Drug intelligence / Profile preview

LY3463251

Development stage: Discontinued
Lead developer: Eli Lilly
Modality: Fc Fusion Proteins → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

LY3463251 is a GDF15 analog and a potent agonist at the GFRAL/RET receptor. It is designed to modulate energy balance by decreasing food intake and body weight. Developed by Eli Lilly and Company, it was initially investigated for treating overweight and obesity. The drug is administered subcutaneously and has shown modest weight loss effects in clinical trials.

Other names: LY 3463251LY3463251LY-3463251

Targets

GFRAL (Glial-derived neurotrophic factor family receptor alpha-like/ret receptor complex)RET (Rearranged during transfection receptor tyrosine kinase)

Beyond the preview

Go deeper on LY3463251.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY3463251.

Explore the full profile